Milestone Pharmaceuticals Inc. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
Milestone Pharmaceuticals Inc. (MIST) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $184.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-08-12
- Milestone Pharmaceuticals Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2026-06-30 was $0.00.
- Milestone Pharmaceuticals Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2026-03-31 was $184.00K, a 31.43% increase year-over-year.
- Milestone Pharmaceuticals Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-12-31 was $0.00.
- Milestone Pharmaceuticals Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-09-30 was $160.00K, a 116.22% increase year-over-year.
- Milestone Pharmaceuticals Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $300.00K, a 57.07% increase from fiscal 2024.
- Milestone Pharmaceuticals Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $191.00K, a 51.40% decline from fiscal 2023.
- Milestone Pharmaceuticals Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $393.00K.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $184.00K 10-Q · filed 2026-08-12 | $184.00K derived: sum of 3 quarters · filed 2026-08-12 | $344.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $184.00K 10-Q · filed 2026-05-13 | $184.00K derived: sum of 2 quarters · filed 2026-05-13 | $344.00K derived: sum of 3 quarters · filed 2026-05-13 | $344.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $160.00K derived: sum of 2 quarters · filed 2026-03-20 | $160.00K derived: sum of 3 quarters · filed 2026-08-12 | $300.00K 10-K · filed 2026-03-20 |
| 2025-09-30 | $160.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $160.00K derived: sum of 2 quarters · filed 2026-08-12 | $300.00K 10-Q · filed 2025-11-12 | $300.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $140.00K 10-Q · filed 2026-08-12 | $140.00K derived: sum of 3 quarters · filed 2026-08-12 | $214.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $140.00K 10-Q · filed 2026-05-13 | $140.00K derived: sum of 2 quarters · filed 2026-05-13 | $214.00K derived: sum of 3 quarters · filed 2026-05-13 | $214.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $74.00K derived: sum of 2 quarters · filed 2026-03-20 | $74.00K derived: sum of 3 quarters · filed 2026-03-20 | $191.00K 10-K · filed 2026-03-20 |
| 2024-09-30 | $74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $74.00K derived: sum of 2 quarters · filed 2025-11-12 | $191.00K 10-Q · filed 2025-11-12 | $191.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $117.00K 10-Q · filed 2025-08-12 | $117.00K derived: sum of 3 quarters · filed 2025-08-12 | $382.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $117.00K 10-Q · filed 2025-05-14 | $117.00K derived: sum of 2 quarters · filed 2025-05-14 | $382.00K derived: sum of 3 quarters · filed 2025-05-14 | $381.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $265.00K derived: sum of 2 quarters · filed 2025-03-13 | $264.00K derived: sum of 3 quarters · filed 2025-03-13 | $393.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $265.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $264.00K derived: sum of 2 quarters · filed 2024-11-12 | $393.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $128.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $129.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |